| Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals … E Bolla, AG Semb, AM Kerola, E Ikdahl, M Petri, GJ Pons-Estel, ... The Lancet Rheumatology, 2024 | 1 | 2024 |
| Rheumatoid Arthritis, Antirheumatic Drugs and Risk of Dementia: A Registry‐based Study N Zhu, M Eriksdotter, S Garcia‐Ptacek, S Mitra, S Ajeganova, JJ Carrero, ... Alzheimer's & Dementia 19, e079527, 2023 | | 2023 |
| Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody … S Ajeganova, M Andersson, K Forslind, I Gjertsson, BM Nyhäll-Wåhlin, ... BMC rheumatology 7 (1), 23, 2023 | 2 | 2023 |
| OP0129 Effectiveness of COBRA-Slim with or without early access to a temporary 6-month course of etanercept in early RA: primary outcome of the 2-year, pragmatic, randomised … D Bertrand, J Joly, B Neerinckx, P Durez, J Lenaerts, R Joos, K Thevissen, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 85-85, 2023 | 1 | 2023 |
| How to manage patients perceived as having a mild form of early arthritis? D De Cock, S Ajeganova, P Verschueren Rheumatology 62 (6), 2025-2026, 2023 | | 2023 |
| Erosion-free rheumatoid arthritis: clinical and conceptional implications—a BARFOT study B Svensson, MLE Andersson, I Gjertsson, I Hafström, S Ajeganova, ... BMC rheumatology 6 (1), 88, 2022 | 10 | 2022 |
| Misdiagnosis of rheumatoid arthritis in a long-term cohort of early arthritis based on the ACR-1987 classification criteria M Leu Agelii, I Hafström, B Svensson, S Ajeganova, K Forslind, ... Open access rheumatology: research and reviews, 187-194, 2022 | 2 | 2022 |
| Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events S Ajeganova, MLE Andersson, J Frostegård, I Hafström Arthritis Research & Therapy 23, 1-11, 2021 | 3 | 2021 |
| Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms J Frostegård, S Ahmed, I Hafström, S Ajeganova, M Rahman Arthritis Research & Therapy 23, 1-9, 2021 | 26 | 2021 |
| Effects of atorvastatin on T‐Cell activation and apoptosis in systemic Lupus Erythematosus and novel simulated interactions with C‐reactive protein and interleukin 6 J Sun, P Kumar Panda, S Kumar Samal, R Ahuja, S Ajeganova, ... ACR Open Rheumatology 3 (9), 642-653, 2021 | 8 | 2021 |
| Team Rehabilitation in Inflammatory Arthritis Benefits Functional Outcomes Along With Improved Body Composition Associated With Improved Cardiorespiratory Fitness S Ajeganova, M Wörnert, I Hafström The Journal of Rheumatology 48 (9), 1371-1378, 2021 | | 2021 |
| Influence of age and sex on disease course and treatment in rheumatoid arthritis J Nilsson, MLE Andersson, I Hafström, B Svensson, K Forslind, ... Open access rheumatology: research and reviews, 123-138, 2021 | 45 | 2021 |
| Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures … S Ajeganova, I Hafström, J Frostegård Lupus Science & Medicine 8 (1), e000454, 2021 | 42 | 2021 |
| Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance S Ajeganova, A De Becker, R Schots Therapeutic Advances in Musculoskeletal Disease 12, 1759720X20974858, 2020 | 16 | 2020 |
| Pcsk9 is associated with disease activity and implicated in immune activation and cardiovascular disease in systemic lupus erythematosus J Frostegard, J Frostegard, M Rahman, I Hafstrom, S Ajeganova, A Liu European Heart Journal 41 (Supplement_2), ehaa946. 3623, 2020 | 1 | 2020 |
| Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus A Liu, M Rahman, I Hafström, S Ajeganova, J Frostegård Lupus 29 (8), 825-835, 2020 | 29 | 2020 |
| SAT0026 HIGHER LEVELS OF NATURAL ANTI-PHOSPHORYLCHOLINE ANTIBODIES ARE ASSOCIATED WITH LOWER RISK OF INCIDENT CARDIOVASCULAR EVENTS IN YOUNGER PATIENTS WITH RHEUMATOID ARTHRITIS S Ajeganova, M Andersson, J Frostegård, I Hafström Annals of the Rheumatic Diseases 79 (Suppl 1), 943-943, 2020 | | 2020 |
| AB0129 PCSK9 IS ASSOCIATED WITH DISEASE ACTIVITY AND IMPLICATED IN IMMUNE ACTIVATION IN SYSTEMIC LUPUS ERYTHEMATOSUS A Liu, M Rahman, I Hafström, S Ajeganova, J Frostegård Annals of the Rheumatic Diseases 79 (Suppl 1), 1365-1366, 2020 | | 2020 |
| SAT0612 TEAM-REHABILITATION BENEFITS BODY COMPOSITION AND FUNCTIONAL OUTCOME BEYOND TIME OF THE REHABILITATION PERIOD IN INFLAMMATORY ARTHRITIS, OF WHICH BODY COMPOSITION IS … S Ajeganova, M Wörnert, I Hafström Annals of the Rheumatic Diseases 79 (Suppl 1), 1266-1267, 2020 | | 2020 |
| Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El … O Palomares, E Untersmayr, J Gutermuth, I Agache, S Ajeganova, ... Allergy 75 (4), 2020 | 22 | 2020 |
